

## (11) **EP 1 764 092 A3**

(12)

### **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3: **27.06.2007 Bulletin 2007/26** 

(51) Int Cl.: **A61K 31/00** (2006.01)

A61P 25/28 (2006.01)

(43) Date of publication A2: **21.03.2007 Bulletin 2007/12** 

(21) Application number: 06025394.5

(22) Date of filing: 19.07.2002

(84) Designated Contracting States:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
IE IT LI LU MC NL PT SE SK TR

(30) Priority: 19.07.2001 GB 0117645

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: 02749036.6 / 1 408 938

(71) Applicant: ISIS INNOVATION LIMITED Ewert Place Summertown Oxford OX2 7LG (GB) (72) Inventor: Nagy, Zsuzsanna Birmingham B17 8EB (GB)

(74) Representative: White, Nina Louise Boult Wade Tennant Verulam Gardens 70 Gray's Inn Road London WC1X 8BT (GB)

#### (54) Selecting compounds for treatment of Alzheimer's disease

(57) The invention relates to screening methods which can be used to select pharmaceutically active agents for use in treating Alzheimer's Disease in a patient. In particular the invention relates to a method of screening a panel of pharmaceutical agents in non-neu-

ronal cells taken from an Alzheimer's Disease patient that it is desired to treat, in order to identify which agent is likely to be of most benefit in that patient.

EP 1 764 092 A3



## **EUROPEAN SEARCH REPORT**

Application Number EP 06 02 5394

ļ	DOCUMENTS CONSID	ERED TO BE F	RELEVANT		
Category	Citation of document with ir of relevant passa		opriate,	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	ARENDT TH ET AL: "repressing GO-G1 tr strategy for AD?." EUROPEAN JOURNAL OF vol. 12, no. Supple 522, XP001117411 Meeting of the Fede Neuroscience Societ 24-28, 2000 ISSN: 0953-816X * abstract *	eansition: A  NEUROSCIENCE  Ment 11, 2000  Pration of Eur	therapeutic E, 9, page ropean	1,2	INV. A61K31/00 A61P25/28
X	COPANI A. ET AL: "by.betaamyloid ca FASEB JOURNAL,, vol. 13, no. 15, 19 XP001106213 * abstract * * page 2231, right- 16-29 *	uses neurona 199, pages 22	1 death." 25-2234,	1,2	
	* page 2232, right-	hand column,	lines 3-8		TECHNICAL FIELDS SEARCHED (IPC)
X	W0 94/00095 A (CORT TECH RES INST (US); 6 January 1994 (199 * page 219, lines 2 * page 152, line 24 * page 208, line 15 * claims 1-12 *	LYNCH GARY 04-01-06) 0-10 * 0-10 - page 153,	(US); PO) line 4 *	1,2	A61P A61K
			-/		
	The present search report has l	•			
	Place of search		oletion of the search		Examiner
X : parti Y : parti docu A : tech	Munich  ATEGORY OF CITED DOCUMENTS  cularly relevant if taken alone cularly relevant if combined with anot ment of the same category nological background written disclosure	8 May	T: theory or principle E: earlier patent doc after the filling date D: document cited in L: document of the sa	underlying the i ument, but public the application r other reasons	shed on, or

EPO FORM 1503 03.82 (P04C01) **ω** 



## **EUROPEAN SEARCH REPORT**

Application Number EP 06 02 5394

	DOCUMENTS CONSIDER		Del	OL ADDIELO ATION OF THE
ategory	Citation of document with indica of relevant passages		Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
	KAWADA, MANABU ET AL: Antitumor Compound, Re Levels, Arrests Cell ( and Inhibits Anchorage of Human Tumor Cells" EXPERIMENTAL CELL RES 240-247, 1999, XP00110 * abstract *	educes Cyclin D1 Cycle at G1 Phase, e-Independent Growth EARCH (1999), 249(2)	1,2	
	WO 00/19200 A1 (MITOKO A [US]; MILLER SCOTT N SOUMITRA) 6 April 2000 * claims; examples 6-9	W [US]; GHOSH D (2000-04-06)	3,4	
	WO 99/37294 A (MITOKO SOUMITRA S [US]; MILL DAVIS ROBERT) 29 July * examples 4,5 *	ER SCOTT W [US];	3,4	
				TECHNICAL FIELDS
				SEARCHED (IPC)
			$\dashv$	
	The present search report has been	Date of completion of the search	1 ,	Examiner
	Munich	8 May 2007	Her	rrera, Suzanne
X : parti Y : parti docu	ATEGORY OF CITED DOCUMENTS  icularly relevant if taken alone icularly relevant if combined with another iment of the same category nological background	T : theory or princip E : earlier patent d after the filing d D : document cited L : document cited	ocument, but publi ate in the application for other reasons	
	-written disclosure rmediate document	& : member of the		



Application Number

EP 06 02 5394

CLAIMS INCURRING FEES
The present European patent application comprised at the time of filling more than ten claims.
Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.
LACK OF UNITY OF INVENTION
The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:
see sheet B
All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:



# LACK OF UNITY OF INVENTION SHEET B

**Application Number** 

EP 06 02 5394

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. claims: 1-2

Screening method for drugs to use in the treatment of alzheimer using non-neuronal cells and analysing the regulation of the G1/S transition

---

2. claims: 3-4

Screening method for drugs to use in the treatment of alzheimer using SH-Sy5Y neuroblastoma cells and testing for parameters such as cell survival, apoptosis and different other parameters

---

#### ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 06 02 5394

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

08-05-2007

WO 9400095 A WO 0019200 A1	06-01-1994	AU CA EP JP	4544993 2138124		24-01-199
WO 0019200 A1	06 04 2000		0650368 9500087	A1	06-01-199 03-05-199 07-01-199
	06-04-2000	AU CA EP JP US	6162899 2345066 1116027 2002525630 2003044776	A1 A1 T	17-04-200 06-04-200 18-07-200 13-08-200 06-03-200
WO 9937294 A	29-07-1999	AU CA EP JP	2474399 2319131 1051165 2002501018	A1 A2	09-08-199 29-07-199 15-11-200 15-01-200

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82